The Russian private company Betuvax announced today that it has begun its clinical trials Betuvax-CoV-2 vaccine against coronavirus, the second vaccine of its kind produced by a private Russian company, broadcasts the TASS agency.
The first and second phase trials, which are carried out under the supervision of the “Human Stem Cell Institute”, will involve 170 people, aged 18 – 60 years old, from the cities of St. Petersburg and Perm. The tests are expected to last until September next year.
Earlier, vaccine makers announced that they were expecting minimal side effects from the use of this vaccine due to of its special composition.
“It contains only coronavirus surface antigens, which reduces the protein content and therefore reduces the allergenic activity of the preparation. The vaccine does not contain viruses and viral vectors, genetic material in the form of DNA and RNA, excessive antigenic load, additional preservatives, stabilizers and inorganic additives (adjuvants) substances“, which minimizes the risks of side effects”, the company clarified to TASS.
THE Biocad, another private company, began clinical trials of its own COVID-19 vaccine last month, Interfax reported.
It is pointed out that the Russia, so far, has approves vaccines developed by three state institutes, including Sputnik-V, in two doses.
Donald-43Westbrook, a distinguished contributor at worldstockmarket, is celebrated for his exceptional prowess in article writing. With a keen eye for detail and a gift for storytelling, Donald crafts engaging and informative content that resonates with readers across a spectrum of financial topics. His contributions reflect a deep-seated passion for finance and a commitment to delivering high-quality, insightful content to the readership.
